Epics Therapeutics
Pre-clinicalEPICS Therapeutics pioneers best-in-class small-molecule modulators of RNA epigenetics, with lead program EP102, a METTL3 inhibitor now advancing in patients with solid tumors.
Founded
2018
Focus
RNA & Gene Therapy
About
EPICS Therapeutics pioneers best-in-class small-molecule modulators of RNA epigenetics, with lead program EP102, a METTL3 inhibitor now advancing in patients with solid tumors.
Company Info
TypePrivate
Founded2018
LocationLeuven, Belgium
StagePre-clinical
Contact
SIMILAR COMPANIES
Miracor Medical
Pre-clinical · Zaventem
AML Clinical Services
Pre-clinical · Leuven
Anacura
Pre-clinical · Ghent
Aseptic Technologies
Pre-clinical · Gembloux
Aspect Analytics
Pre-clinical · Leuven
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile